Zlatoslava O. Shaienko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zlatoslava O. Shaienko has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Halyna Yu. Morokhovets
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
3 shared publications - Oksana V. Muravlova
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
3 shared publications - A. M. Urbanovych
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
2 shared publications - A.H. Haletska
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
2 shared publications - Alan R. Shuldiner
Regeneron Genetics Center, Tarrytown, USA
2 shared publications - Alina Huklyvska
Department of Biology, Uzhhorod National University, Uzhhorod, Ukraine
2 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Springer Nature in Metabologia
- Vol. 2 (1) , 20
Correction: A collaborative genomics platform for type 1 diabetes in Eastern and Central Europe
- 24 October 2026
- Published by Springer Nature in Metabologia
- Vol. 2 (1) , 20
Open AccessCorrection: A collaborative genomics platform for type 1 diabetes in Eastern and Central Europe
- Open Access
- 18 September 2026
- Published by Springer Nature in Metabologia
- Vol. 2 (1) , 14
A collaborative genomics platform for type 1 diabetes in Eastern and Central Europe
- 18 September 2026
- Published by Springer Nature in Metabologia
- Vol. 2 (1) , 14
Open AccessA collaborative genomics platform for type 1 diabetes in Eastern and Central Europe
- Open Access
- 13 August 2026
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 5,p. 69-77
LONG-TERM EFFECTS OF QUERCETIN ON OXIDATIVE STRESS PARAMETERS AND NITRIC OXIDE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Introduction. Type 2 diabetes mellitus is associated with oxidative stress, impaired antioxidant defence, and dysregulation of nitric oxide metabolism, all of which contribute to the development of vascular and metabolic complications. The use of bioflavonoids, particularly quercetin, represents a promising approach for correcting these disturbances; however, the duration of persistence of its effects after treatment completion requires further investigation.Aim. The aim of the study was to evaluate the long-term effects of quercetin on oxidative stress parameters, antioxidant defence, and nitric oxide metabolism in patients with type 2 diabetes mellitus three months after completion of treatment.Materials and methods. The study involved 29 patients with type 2 diabetes mellitus, with a mean age of 59.41 ± 1.8 years; among them, 17 were men, and 12 were women. The mean duration of diabetes mellitus was 10.07 ± 1.16 years, and the mean body mass index was 30.69 ± 0.9 kg/m². Patients received quercetin in the form of the pharmaceutical preparation “Quertin” at a dose of one tablet twice daily for 20 days. Biochemical parameters were assessed before treatment, immediately after completion of therapy and 3 months after treatment. The activity of inducible NO synthase, constitutive NO synthase isoforms, arginase, superoxide dismutase and catalase, as well as malondialdehyde concentration, were determined.Results. Following treatment, superoxide dismutase activity increased from 7.185 ± 0.174 to 15.54 ± 0.479 and remained elevated at 13.08 ± 0.381 after 3 months. Catalase activity increased from 1.538 ± 0.062 to 3.024 (2.924-3.137), while after 3 months it was 2.581 ± 0.073. The level of malondialdehyde decreased from 29.12 (26.79-32.87) to 14.03 ± 0.391 and, after 3 months, remained lower than baseline at 15.03 ± 0.549. After 3 months, the activity of constitutive NO synthase isoforms increased to 0.068 (0.055–0.189), whereas arginase activity remained below baseline values. Integral comparison of the parameters at the three time points revealed statistically significant differences (H = 45.97; p < 0.0001). Differences between the post-treatment values and those obtained after 3 months were not statistically significant (p = 0.2488). Conclusions. The use of quercetin in patients with type 2 diabetes mellitus was associated with sustained positive changes in antioxidant defence parameters, lipid peroxidation and nitric oxide metabolism 3 months after completion of treatment.
- 13 August 2026
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 5,p. 69-77
Open AccessLONG-TERM EFFECTS OF QUERCETIN ON OXIDATIVE STRESS PARAMETERS AND NITRIC OXIDE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Introduction. Type 2 diabetes mellitus is associated with oxidative stress, impaired antioxidant defence, and dysregulation of nitric oxide metabolism, all of which contribute to the development of vascular and metabolic complications. The use of bioflavonoids, particularly quercetin, represents a promising approach for correcting these disturbances; however, the duration of persistence of its effects after treatment completion requires further investigation.Aim. The aim of the study was to evaluate the long-term effects of quercetin on oxidative stress parameters, antioxidant defence, and nitric oxide metabolism in patients with type 2 diabetes mellitus three months after completion of treatment.Materials and methods. The study involved 29 patients with type 2 diabetes mellitus, with a mean age of 59.41 ± 1.8 years; among them, 17 were men, and 12 were women. The mean duration of diabetes mellitus was 10.07 ± 1.16 years, and the mean body mass index was 30.69 ± 0.9 kg/m². Patients received quercetin in the form of the pharmaceutical preparation “Quertin” at a dose of one tablet twice daily for 20 days. Biochemical parameters were assessed before treatment, immediately after completion of therapy and 3 months after treatment. The activity of inducible NO synthase, constitutive NO synthase isoforms, arginase, superoxide dismutase and catalase, as well as malondialdehyde concentration, were determined.Results. Following treatment, superoxide dismutase activity increased from 7.185 ± 0.174 to 15.54 ± 0.479 and remained elevated at 13.08 ± 0.381 after 3 months. Catalase activity increased from 1.538 ± 0.062 to 3.024 (2.924-3.137), while after 3 months it was 2.581 ± 0.073. The level of malondialdehyde decreased from 29.12 (26.79-32.87) to 14.03 ± 0.391 and, after 3 months, remained lower than baseline at 15.03 ± 0.549. After 3 months, the activity of constitutive NO synthase isoforms increased to 0.068 (0.055–0.189), whereas arginase activity remained below baseline values. Integral comparison of the parameters at the three time points revealed statistically significant differences (H = 45.97; p < 0.0001). Differences between the post-treatment values and those obtained after 3 months were not statistically significant (p = 0.2488). Conclusions. The use of quercetin in patients with type 2 diabetes mellitus was associated with sustained positive changes in antioxidant defence parameters, lipid peroxidation and nitric oxide metabolism 3 months after completion of treatment.
- Open Access
- 30 March 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 36-43
Disruption of the nitric oxide cycle and oxidative stress in patients with prediabetes: prospects for early correction with quercetin
Prediabetes is linked to early metabolic and vascular issues, with oxidative and nitrosative stress and disruption of the nitric oxide cycle being central. These factors contribute to endothelial dysfunction and higher cardiovascular risk. Finding strategies for early correction of these changes is a critical focus in modern metabolic medicine. Objective — to investigate the characteristics of oxidative stress and nitric oxide production in patients with prediabetes and evaluate the potential for their early correction with quercetin. Materials and methods. Thirty-two patients were examined and divided into a control group (n=15) and a main group (n=17, prediabetes). Prediabetes was diagnosed following ADA recommendations and the National Clinical Protocol. Patients in the main group received quercetin for 20 days. MDA levels, SOD, catalase, cNOS, iNOS, and arginase activity were assessed before and after treatment. Non-parametric statistical methods, correlation analysis, and ROC analysis were applied. Results. Before treatment, patients with prediabetes showed increased iNOS activity, elevated MDA, and altered antioxidant enzyme activities compared to controls. Following quercetin administration, iNOS activity decreased 5.9-fold (p<0.0001), MDA concentration decreased by 31.0% (p<0.0001), SOD activity decreased by 37.8% (p<0.0001), and catalase activity decreased by 21.6% (p<0.0001), while arginase activity increased by 82.0% (p<0.0001). cNOS activity remained unchanged. ROC analysis demonstrated high diagnostic informativeness of MDA, iNOS, and arginase (AUC 0.926 — 1.0). Conclusions. Prediabetes involves increased oxidative and nitrosative stress, along with an imbalance in the nitric oxide cycle. Administering quercetin effectively addresses these issues in their early stages, making it a useful option for preventing the progression of metabolic and vascular complications.
- 30 March 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 36-43
Open AccessDisruption of the nitric oxide cycle and oxidative stress in patients with prediabetes: prospects for early correction with quercetin
Prediabetes is linked to early metabolic and vascular issues, with oxidative and nitrosative stress and disruption of the nitric oxide cycle being central. These factors contribute to endothelial dysfunction and higher cardiovascular risk. Finding strategies for early correction of these changes is a critical focus in modern metabolic medicine. Objective — to investigate the characteristics of oxidative stress and nitric oxide production in patients with prediabetes and evaluate the potential for their early correction with quercetin. Materials and methods. Thirty-two patients were examined and divided into a control group (n=15) and a main group (n=17, prediabetes). Prediabetes was diagnosed following ADA recommendations and the National Clinical Protocol. Patients in the main group received quercetin for 20 days. MDA levels, SOD, catalase, cNOS, iNOS, and arginase activity were assessed before and after treatment. Non-parametric statistical methods, correlation analysis, and ROC analysis were applied. Results. Before treatment, patients with prediabetes showed increased iNOS activity, elevated MDA, and altered antioxidant enzyme activities compared to controls. Following quercetin administration, iNOS activity decreased 5.9-fold (p<0.0001), MDA concentration decreased by 31.0% (p<0.0001), SOD activity decreased by 37.8% (p<0.0001), and catalase activity decreased by 21.6% (p<0.0001), while arginase activity increased by 82.0% (p<0.0001). cNOS activity remained unchanged. ROC analysis demonstrated high diagnostic informativeness of MDA, iNOS, and arginase (AUC 0.926 — 1.0). Conclusions. Prediabetes involves increased oxidative and nitrosative stress, along with an imbalance in the nitric oxide cycle. Administering quercetin effectively addresses these issues in their early stages, making it a useful option for preventing the progression of metabolic and vascular complications.
- Open Access
- 30 June 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 71
Systemic inflammatory indices: a new perspective on routine diagnostics in patients with carbohydrate metabolism disorders
CONFERENCE ABSTRACTS • ТЕЗИ КОНФЕРЕНЦІЇ Цукровий діабет 2 типу (ЦД2)-поширене метаболічне захворювання, що супроводжується хронічним низькоінтенсивним запаленням. Такий тип
- 30 June 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 71
Open AccessSystemic inflammatory indices: a new perspective on routine diagnostics in patients with carbohydrate metabolism disorders
CONFERENCE ABSTRACTS • ТЕЗИ КОНФЕРЕНЦІЇ Цукровий діабет 2 типу (ЦД2)-поширене метаболічне захворювання, що супроводжується хронічним низькоінтенсивним запаленням. Такий тип
- Open Access
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 259-264
Diagnostic and prognostic value of inflammatory indices in patients with prediabetes and type 2 diabetes mellitus
Background. Type 2 diabetes mellitus (T2DM) is characterized by chronic low-grade inflammation, which significantly contributes to the development of insulin resistance and progressive metabolic dysfunction. Inflammatory indices derived from complete blood count parameters may serve as accessible and cost-effective tools for assessing meta-inflammation. Objective: to determine the levels of systemic immune-inflammation index (SII) and systemic immune-inflammation response index (SIRI) in patients with prediabetes and T2DM in order to assess their diagnostic and prognostic value. Materials and methods. This study included 60 participants divided into three groups: type 2 diabetes, prediabetes, and a control group. The levels of SII, SIRI, HbA1c, arginase, inducible nitric oxide synthase, and other metabolic markers were measured. Statistical methods included Kruskal-Wallis test, receiver operating characteristic (ROC) analysis, principal component analysis (PCA), and Spearman correlation. Results. SII was significantly elevated in the T2DM group compared to both the control (p = 0.008) and the prediabetes group (p = 0.2414), indicating the progression of systemic inflammation alongside glycemic dysregulation. Although SIRI did not demonstrate significant between-group differences, it showed a strong correlation with SII in the T2DM group (R = 0.72; p < 0.001). SII is important in the PCA alongside HbA1c and arginase, and ROC analysis for SII revealed its moderate ability to distinguish between diabetic and healthy individuals (AUC = 0.719). Conclusions. SII may be considered a promising and accessible biomarker for early diagnosis and assessment of inflammation in patients with impaired glucose metabolism. ROC analysis data demonstrated moderate diagnostic ability of SII in distinguishing people with T2DM from healthy individuals, which opens opportunities for its use in screening programs, especially at the primary health care level. Inflammatory indices (especially SII) are promising as additional, non-invasive markers for early diagnosis, prognosis and monitoring of therapy effectiveness in patients with carbohydrate metabolism disorders. Their widespread implementation may contribute to personalization of treatment approaches and reduce the risk of cardiovascular complications. Additional studies are needed to develop optimal threshold values of indices that will allow them to be included in standard algorithms for examining patients with impaired carbohydrate metabolism.
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 259-264
Open AccessDiagnostic and prognostic value of inflammatory indices in patients with prediabetes and type 2 diabetes mellitus
Background. Type 2 diabetes mellitus (T2DM) is characterized by chronic low-grade inflammation, which significantly contributes to the development of insulin resistance and progressive metabolic dysfunction. Inflammatory indices derived from complete blood count parameters may serve as accessible and cost-effective tools for assessing meta-inflammation. Objective: to determine the levels of systemic immune-inflammation index (SII) and systemic immune-inflammation response index (SIRI) in patients with prediabetes and T2DM in order to assess their diagnostic and prognostic value. Materials and methods. This study included 60 participants divided into three groups: type 2 diabetes, prediabetes, and a control group. The levels of SII, SIRI, HbA1c, arginase, inducible nitric oxide synthase, and other metabolic markers were measured. Statistical methods included Kruskal-Wallis test, receiver operating characteristic (ROC) analysis, principal component analysis (PCA), and Spearman correlation. Results. SII was significantly elevated in the T2DM group compared to both the control (p = 0.008) and the prediabetes group (p = 0.2414), indicating the progression of systemic inflammation alongside glycemic dysregulation. Although SIRI did not demonstrate significant between-group differences, it showed a strong correlation with SII in the T2DM group (R = 0.72; p < 0.001). SII is important in the PCA alongside HbA1c and arginase, and ROC analysis for SII revealed its moderate ability to distinguish between diabetic and healthy individuals (AUC = 0.719). Conclusions. SII may be considered a promising and accessible biomarker for early diagnosis and assessment of inflammation in patients with impaired glucose metabolism. ROC analysis data demonstrated moderate diagnostic ability of SII in distinguishing people with T2DM from healthy individuals, which opens opportunities for its use in screening programs, especially at the primary health care level. Inflammatory indices (especially SII) are promising as additional, non-invasive markers for early diagnosis, prognosis and monitoring of therapy effectiveness in patients with carbohydrate metabolism disorders. Their widespread implementation may contribute to personalization of treatment approaches and reduce the risk of cardiovascular complications. Additional studies are needed to develop optimal threshold values of indices that will allow them to be included in standard algorithms for examining patients with impaired carbohydrate metabolism.
- Open Access
- 4 March 2024
- Published by Publishing House Zaslavsky in CHILD`S HEALTH
- Vol. 19 (1) , 36-39
A clinical case of persistent Lyme disease in a child
Background. The relevance of the study is due to the frequent occurrence of Lyme disease (neuroborreliosis) in the spring-autumn period. Official record of Lyme disease in Ukraine has been conducted since 2000, although the first cases were identified in the 1990s. From 2001 to 2023, the incidence of Lyme borreliosis in Ukraine increased almost by 35 times. Materials and methods. The authors conducted a retrospective analysis of statistical data on Lyme borreliosis morbidity from 2000 to 2023 and the most common cases of infectious pathology in children during this period. As pediatric infectious disease specialists, the authors present a clinical case recently observed in the pediatric infectious unit in Poltava. Results. The diagnosis of Lyme borreliosis is made based on a characteristic clinical picture and a serological confirmation. The latter is crucial in the diagnosis of Lyme borreliosis and includes 2 stages. The first stage is the assessment of immunoglobulin M and G titers by the immunofluorescence assay (IFA). If the result is negative, further investigation is conducted within the first 30 days of symptoms onset by repeated IFA 4–6 weeks after the initial test. If the analysis is conducted ≥ 30 days after the onset of symptoms, further examinations are not carried out, and an alternative diagnosis should be suspected. In case of a doubtful or positive IFA result, the diagnosis is further confirmed by the Western blotting (the second stage). The authors present a case report of a 6-year-old girl M., hospitalized in the pediatric infectious unit of the CE “Municipal Clinical Hospital 1” (Poltava) in March 2023 with a diagnosis of Lyme disease (systemic tick-borne borreliosis), early disseminated stage, myalgia, arthralgia, subacute course, moderate severity. Acetonemic syndrome. Stage 1 deficiency anemia. Metabolic cardiomyopathy. Speech development delay. Conclusions. Therefore, it is crucial to recognize Lyme disease with a progressing or remitting disseminated form, as specific therapeutic approaches exist that are effective for this disabling condition.
- 4 March 2024
- Published by Publishing House Zaslavsky in CHILD`S HEALTH
- Vol. 19 (1) , 36-39
Open AccessA clinical case of persistent Lyme disease in a child
Background. The relevance of the study is due to the frequent occurrence of Lyme disease (neuroborreliosis) in the spring-autumn period. Official record of Lyme disease in Ukraine has been conducted since 2000, although the first cases were identified in the 1990s. From 2001 to 2023, the incidence of Lyme borreliosis in Ukraine increased almost by 35 times. Materials and methods. The authors conducted a retrospective analysis of statistical data on Lyme borreliosis morbidity from 2000 to 2023 and the most common cases of infectious pathology in children during this period. As pediatric infectious disease specialists, the authors present a clinical case recently observed in the pediatric infectious unit in Poltava. Results. The diagnosis of Lyme borreliosis is made based on a characteristic clinical picture and a serological confirmation. The latter is crucial in the diagnosis of Lyme borreliosis and includes 2 stages. The first stage is the assessment of immunoglobulin M and G titers by the immunofluorescence assay (IFA). If the result is negative, further investigation is conducted within the first 30 days of symptoms onset by repeated IFA 4–6 weeks after the initial test. If the analysis is conducted ≥ 30 days after the onset of symptoms, further examinations are not carried out, and an alternative diagnosis should be suspected. In case of a doubtful or positive IFA result, the diagnosis is further confirmed by the Western blotting (the second stage). The authors present a case report of a 6-year-old girl M., hospitalized in the pediatric infectious unit of the CE “Municipal Clinical Hospital 1” (Poltava) in March 2023 with a diagnosis of Lyme disease (systemic tick-borne borreliosis), early disseminated stage, myalgia, arthralgia, subacute course, moderate severity. Acetonemic syndrome. Stage 1 deficiency anemia. Metabolic cardiomyopathy. Speech development delay. Conclusions. Therefore, it is crucial to recognize Lyme disease with a progressing or remitting disseminated form, as specific therapeutic approaches exist that are effective for this disabling condition.
- Open Access
- 30 October 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (6) , 448-454
Diabetes mellitus and COVID-19: living with double risk
Background. The purpose is to analyze and summarize the studies conducted to determine the impact of COVID-19 on the course of diabetes mellitus and the manifestations of chronic complications of this disease. Materials and methods. We did the search in PubMed and ScienceDirect databases using the following line: “SARS-CoV-2 or COVID-19 and diabetes or hyperglycemia”. Results. It was found that in patients with diabetes, the severity of COVID-19 is increased. In particular, the number of those who needed intensive care or artificial ventilation has elevated. The same negative trend is noted for the overall mortality rate in patients with diabetes. It has been found that COVID-19 contributes to an increase in the development of diabetes, including diabetic ketoacidosis, hyperosmolar syndrome, brain stroke and mental health disorders, which can potentiate the effect of COVID-19 in enhancing the manifestations of diabetes and double risk for these patients. Along with this, the common pathways of the pathogenesis of diabetes and COVID-19 determine the bidirectionality of the interaction in their comorbidity. Conclusions. We have demonstrated numerous links between COVID-19 pathogenetic mechanisms and diabetes. Despite this, current research shows only modest evidence of an increased risk of metabolic, neurological, and psychiatric complications in patients with diabetes who had COVID-19. However, along with the direct impact of patients’ infection, the conditions of pandemic are also affected, which complicate access to the necessary care and should be taken into account when studying the clinical consequences of COVID-19 in patients with diabetes.
- 30 October 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (6) , 448-454
Open AccessDiabetes mellitus and COVID-19: living with double risk
Background. The purpose is to analyze and summarize the studies conducted to determine the impact of COVID-19 on the course of diabetes mellitus and the manifestations of chronic complications of this disease. Materials and methods. We did the search in PubMed and ScienceDirect databases using the following line: “SARS-CoV-2 or COVID-19 and diabetes or hyperglycemia”. Results. It was found that in patients with diabetes, the severity of COVID-19 is increased. In particular, the number of those who needed intensive care or artificial ventilation has elevated. The same negative trend is noted for the overall mortality rate in patients with diabetes. It has been found that COVID-19 contributes to an increase in the development of diabetes, including diabetic ketoacidosis, hyperosmolar syndrome, brain stroke and mental health disorders, which can potentiate the effect of COVID-19 in enhancing the manifestations of diabetes and double risk for these patients. Along with this, the common pathways of the pathogenesis of diabetes and COVID-19 determine the bidirectionality of the interaction in their comorbidity. Conclusions. We have demonstrated numerous links between COVID-19 pathogenetic mechanisms and diabetes. Despite this, current research shows only modest evidence of an increased risk of metabolic, neurological, and psychiatric complications in patients with diabetes who had COVID-19. However, along with the direct impact of patients’ infection, the conditions of pandemic are also affected, which complicate access to the necessary care and should be taken into account when studying the clinical consequences of COVID-19 in patients with diabetes.
- Open Access
- 30 June 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (4) , 295-299
Aspects of the development of hypothyroid cardiomyopathy associated with chronic systemic inflammation
Background. Cardiovascular manifestations are rated first among the symptoms of hypothyroidism. Since the highest prevalence of both coronary heart disease (CHD) and hypothyroidism is observed in the age group over 50 years old, the problem of combination of these nosologies in older people is increasing. Aim of the study is to investigate the structural and functional state of the left ventricular myocardium in hypothyroidism and CHD associated with chronic systemic inflammation. Materials and methods. To reach the objectives of the study, a randomized controlled clinical trial has been conducted in parallel groups of patients with hypothyroidism, CHD and combination of both. To form the main group, a screening analysis of 556 medical histories of patients with hypothyroidism and CHD during the period of 2006–2015 has been made, which were selected for further study. Results. It has been found that myocardial hypertrophy develops in all groups of patients, a decrease in thyroid function leads to remodeling of the left ventricular myocardium with the development of eccentric hypertrophy and the progression of systolic heart failure in comorbidity. A direct correlation between reduced ejection fraction and elevated interleukin-8 level has been detected. Evaluation of the state of chronic systemic inflammation revealed a significant increase in the level of interleukin-8 in patients with coronary heart disease associated with hypothyroidism (7.66 ± 2.18 pg/ml; p < 0.05). This indicate that the persistence of pro-inflammatory state in patients with combined pathology is a negative prognostic factor for the development of cardiovascular complications. Conclusion. During echocardioscopy of patients with hypothyroidism, the impaired central hemodynamics can be determined by the indicators of the diastolic and systolic heart function. In patients with isolated hypothyroidism and in combination with coronary heart disease, thickening of the left ventricular myocardial walls is noted, which proves the specificity of changes in the heart geometry that leads to the development of eccentric hypertrophy. This can be considered as the marker of a “hypothyroid” heart whose severity can determine the severity of hypothyroidism. Activation of chronic systemic inflammation is more pronounced in conditions of comorbidity, with a negative prognostic effect on the state of the cardiovascular system.
- 30 June 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (4) , 295-299
Open AccessAspects of the development of hypothyroid cardiomyopathy associated with chronic systemic inflammation
Background. Cardiovascular manifestations are rated first among the symptoms of hypothyroidism. Since the highest prevalence of both coronary heart disease (CHD) and hypothyroidism is observed in the age group over 50 years old, the problem of combination of these nosologies in older people is increasing. Aim of the study is to investigate the structural and functional state of the left ventricular myocardium in hypothyroidism and CHD associated with chronic systemic inflammation. Materials and methods. To reach the objectives of the study, a randomized controlled clinical trial has been conducted in parallel groups of patients with hypothyroidism, CHD and combination of both. To form the main group, a screening analysis of 556 medical histories of patients with hypothyroidism and CHD during the period of 2006–2015 has been made, which were selected for further study. Results. It has been found that myocardial hypertrophy develops in all groups of patients, a decrease in thyroid function leads to remodeling of the left ventricular myocardium with the development of eccentric hypertrophy and the progression of systolic heart failure in comorbidity. A direct correlation between reduced ejection fraction and elevated interleukin-8 level has been detected. Evaluation of the state of chronic systemic inflammation revealed a significant increase in the level of interleukin-8 in patients with coronary heart disease associated with hypothyroidism (7.66 ± 2.18 pg/ml; p < 0.05). This indicate that the persistence of pro-inflammatory state in patients with combined pathology is a negative prognostic factor for the development of cardiovascular complications. Conclusion. During echocardioscopy of patients with hypothyroidism, the impaired central hemodynamics can be determined by the indicators of the diastolic and systolic heart function. In patients with isolated hypothyroidism and in combination with coronary heart disease, thickening of the left ventricular myocardial walls is noted, which proves the specificity of changes in the heart geometry that leads to the development of eccentric hypertrophy. This can be considered as the marker of a “hypothyroid” heart whose severity can determine the severity of hypothyroidism. Activation of chronic systemic inflammation is more pronounced in conditions of comorbidity, with a negative prognostic effect on the state of the cardiovascular system.
- Open Access
- 30 May 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (3) , 183-187
The influence of nanodispersed cerium oxide on the development of oxidative stress and the production of nitric oxide in patients with type 2 diabetes mellitus
Background. In the pathogenesis of complications of diabetes mellitus (DM), in addition to glucotoxicity, the development of oxidative stress plays a leading role. Antioxidants have been of great interest for physicians in recent years. Contemporary diabetology have been focused on the search and practical implementation of pathogenetic medications that can affect the main chains of DM and prevent its negative consequences. Purpose of the study is to determine the effect of nanodispersed cerium oxide (NCO) on the production of nitric oxide (NO), the activity of antioxidant enzymes and the intensity of lipid peroxidation in the blood of patients with type 2 diabetes mellitus. Materials and methods. Seventy-two patients aged 36 to 66 years, average age of 55.20±6.82 years, who received treatment at the Municipal Clinical Hospital 2 in Poltava from July to December 2022 have been involved in the study. They have been divided into 2 groups: controls (n=35), which included people without diabetes; experimental group (n=37), which consisted of patients diagnosed with type 2 DM. Results. The use of NCO in patients with type 2 DM significantly reduces the activity of inducible NO synthase in the blood by 34.70% and the activity of arginases by 52.17% compared to the levels before treatment. The use of nanodispersed cerium oxide in the treatment of type 2 DM increases the activity of superoxide dismutase in the blood by 102.74%, and the activity of catalase by 103.04% compared to same indicators in the experimental group before therapy. Notably, blood malondialdehyde was significantly lower (by 2.35 times) compared to the same indicator before treatment. Conclusions. The use of NCO in patients with type 2 diabetes mellitus leads to an increase in antioxidant protection and a decrease in the intensity of lipid peroxidation in blood. NCO reduces the production of nitric oxide from the inducible NO synthase and weakens the competition between NO synthases and arginases for the reaction substrate. The findings of the study justify the need to include antioxidants in the pathogenetic therapy of diabetes mellitus and its complications.
- 30 May 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (3) , 183-187
Open AccessThe influence of nanodispersed cerium oxide on the development of oxidative stress and the production of nitric oxide in patients with type 2 diabetes mellitus
Background. In the pathogenesis of complications of diabetes mellitus (DM), in addition to glucotoxicity, the development of oxidative stress plays a leading role. Antioxidants have been of great interest for physicians in recent years. Contemporary diabetology have been focused on the search and practical implementation of pathogenetic medications that can affect the main chains of DM and prevent its negative consequences. Purpose of the study is to determine the effect of nanodispersed cerium oxide (NCO) on the production of nitric oxide (NO), the activity of antioxidant enzymes and the intensity of lipid peroxidation in the blood of patients with type 2 diabetes mellitus. Materials and methods. Seventy-two patients aged 36 to 66 years, average age of 55.20±6.82 years, who received treatment at the Municipal Clinical Hospital 2 in Poltava from July to December 2022 have been involved in the study. They have been divided into 2 groups: controls (n=35), which included people without diabetes; experimental group (n=37), which consisted of patients diagnosed with type 2 DM. Results. The use of NCO in patients with type 2 DM significantly reduces the activity of inducible NO synthase in the blood by 34.70% and the activity of arginases by 52.17% compared to the levels before treatment. The use of nanodispersed cerium oxide in the treatment of type 2 DM increases the activity of superoxide dismutase in the blood by 102.74%, and the activity of catalase by 103.04% compared to same indicators in the experimental group before therapy. Notably, blood malondialdehyde was significantly lower (by 2.35 times) compared to the same indicator before treatment. Conclusions. The use of NCO in patients with type 2 diabetes mellitus leads to an increase in antioxidant protection and a decrease in the intensity of lipid peroxidation in blood. NCO reduces the production of nitric oxide from the inducible NO synthase and weakens the competition between NO synthases and arginases for the reaction substrate. The findings of the study justify the need to include antioxidants in the pathogenetic therapy of diabetes mellitus and its complications.